Clinical Trial Update: A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults [Phase 1, Phase 2]

View source ↗

Summary

A status update on Moderna's Epstein-Barr Virus vaccine candidate mRNA-1189 in Phase 1/2 trials enrolling healthy adolescents and adults, which is currently ACT…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Infection

Drugs mentioned

• mRNA-1189

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Epstein-Barr Virus Infection | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING